Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Sunday share tips: Octopus Renewables Infrastructure Trust, Bioventix

(Sharecast News) - The Financial Mail on Sunday's Midas column tipped the Octopus Renewables Infrastructure Trust to readers, pointing out its 7% dividend yield and the current valuation of its shares. It also highlighted its diversification, between investments in wind and power but also battery storage and green hydrogen.

That, the tipster said, was designed to provide investors with long-term growth and attractive income.

Its dividend payouts were quarterly and had nearly doubled since Orit floated in 2019, rising consistently in line with inflation.

The share price on the other hand had drifted lower after listing at 100p and then reaching 118p in the spring of 2022.

Midas attributed that to higher interest rates, as well as "general apathy" towards renewable energy stocks.

Nonetheless, in the aggregate its projects were valued at 107p per share or £604m, against a share price of 90.5p.

"Octopus Renewables Infrastructure Trust is in the business of doing good. But the group is equally committed to increasing the value of its assets and providing investors with rising dividends," Midas said.

"As hundreds of policy wonks gather in Dubai over the coming weeks, Orit is turning words into action. At 90.5p, the shares are a buy."

The Sunday Times's Lucy Tobin recommended shares of Bioventix, a biotechnology company focused on 'high affinity' sheep monoclonal antibodies.

Those, she explained were used to conduct blood tests for everything from vitamin D deficiency and fertility to thyroid function or drug abuse.

And despite the risks inherent in backing a tiddler testing firm, the time lag between the development of SMAs and revenues of about five years provided good visibility.

The company was also working on a range of specific antibody projects paid for by pharmaceutical groups, which absorbed the risk.

Its pipeline of future opportunities included promising work on screening candidates for some of the new treatments coming out for Alzheimer's and to keep tabs on disease progression.

"Medical trends towards more complex screening are accelerating; buy Bioventix."

Share this article

Related Sharecast Articles

Sunday newspaper round-up: Middle East, Aston Martin, Defence
(Sharecast News) - Britons must accept that their country was now involved in the Middle East conflict, Tobias Ellwood said. The former defence minister warned that "nobody was in full control" of the growing conflict as more and more countries were sucked in. Ellwood also said that Tehran's strike had taken the conflict into a "new dangerous territory". - Sunday Telegraph
Friday newspaper round-up: Everton, AstraZeneca, Amazon
(Sharecast News) - Everton has paid about £30m in interest charges to an opaque lender associated with a tax exile, corporate records suggest. The charges appear to have reached about £438,000 a week, according to the troubled Premier League club's most recent set of accounts, a figure more than three times the reported wages of the Everton and England goalkeeper Jordan Pickford. - Guardian
Thursday newspaper round-up: Border controls, McKinsey, KPMG
(Sharecast News) - New post-Brexit UK border controls coming into force later this month will cost British businesses £2bn and fuel higher inflation, according to a report warning that UK-EU trade will be damaged as a result. With less than a month before the introduction of new checks on animal and plant products from 30 April, the insurer Allianz Trade said the controls agreed under Boris Johnson's Brexit deal could add 10% to import costs over the first year. - Guardian
Wednesday newspaper round-up: Shoplifting, EnQuest, Klarna
(Sharecast News) - The government is investing more than £55m in expanding facial recognition systems - including vans that will scan crowded high streets - as part of a renewed crackdown on shoplifting. The scheme was announced alongside plans for tougher punishments for serial or abusive shoplifters in England and Wales, including being forced to wear a tag to ensure they do not revisit the scene of their crime, under a new standalone criminal offence of assaulting a retail worker. - Guardian

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.